drugset / Trial / NCT00019669

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019669

Open-labelTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine therapy alone in treating metastatic melanoma. PURPOSE: Phase II trial to compare the effectiveness of melanoma vaccine and interleukin-2 with that of melanoma vaccine alone in treating patients who have metastatic melanoma that has not responded to previous treatment.

Timeline

Start
1999-10
Primary completion
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Intravenous
Subject fowlpox virus vaccine vector Vaccine Intravenous
Subject gp100 antigen Peptide Intravenous

Indications